Developing first-in-class therapies for autoimmune and inflammatory diseases by targeting neutrophil extracellular traps (NETs). Recently named by VCs as 1 of 24 biotech startups poised to take off (Business Insider - August 2021).

Delivering on the promise of RNA medicines leveraging foundational generative AI models, protein engineering and multiplexed in vitro and in vivo capabilities

Novel AAV capsid development to better deliver the promise of gene therapy

Next generation boron neutron capture therapy (BNCT) company seeking to transform oncology care with best-in-class therapeutics, neutron accelerators, and patient positioning.

KdT Ventures invests in early stage companies commercializing frontier science

Engaged by VC firms and their portfolio companies to help with financing, business development, corporate development and product management. Advise therapeutics, TechBio / AI , and digital medicine companies solving large unmet needs with transformative innovations. Project Areas: Biologics, Gene Therapy, Cell Therapy, Artificial Intelligence, Quantum Computing, Biomanufacturing, Small Molecules, Digital HealthIndication Areas: Immunology, Rare Disease, Ophthalmology, Oncology, EndocrinologySelected Engagements:- Neutrolis: Lead Business Advisor. Biologics targeting innate immunity. (Backed by Morningside Ventures, Prefix Capital)- Stealth Structural Biology Company: Advisor / Consultant.- Stealth Gene Therapy Company: Consultant.- Large VC Fund: Consultant. Academic Research Due Diligence.- SwiftScale: Head of Business Development / COVID-19 Treatment Accelerator. Cell-free biomanufacturing. (Acquired by National Resilience, backed by 8VC)- Thermalin: Acting VP of Strategic Development. Novel insulin analogs. (Backed by Sanofi)- Qulab: Consultant. Quantum computing for drug development. (Backed by Cota and Civilization)

ZetaGen Therapeutics (formerly Fusologics), is an early stage life science company developing therapeutic solutions for large unmet needs in the regenerative medicine and oncology markets. Co-founded company, built therapeutics / combination product pipeline and led strategy, financing and operations. ZetaGen was selected to the 2018 cohort of the prestigious MedTech Innovator Accelerator program.

Worked on Castlight's (NYSE: CSLT) Action product, which leverages machine learning, targeted messaging and innovative behavior modification to empower employees of Fortune 500 company to make high quality, high value healthcare decisions. Led creation of scalable experimentation infrastructure, implementation of product analytics and development of customer reporting tools to enable customer engagement, product development and collaboration.

Served as acting CEO for DigiSight. Before rebranding as Verana, DigiSight was a digital health company that created a mobile vision monitoring platform to track ophthalmic disease progression and connect patients to their physicians. Founded by thought-leading ophthalmologists, DigiSight leveraged the cloud and innovative mobile technology to enable improved patient management, care coordination, patient engagement, and value-based healthcare delivery. Verana Health is now backed by GV and Casdin Capital.

Venzyme buillds financiable, innovative companies around early stage life science technologies.

Investigating the mechanisms behind pancreatitis and pancreatic cancer in Dr. Stephen Pandol's Pancreatic Research Group. Second Author on Gastroenterology Paper: "Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage. Gastroenterology. 2011 Mar;140(3):987-97. doi: 10.1053/j.gastro.2010.11.038.